Compare RMT & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMT | ACHV |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.0M | 618.0M |
| IPO Year | N/A | 2018 |
| Metric | RMT | ACHV |
|---|---|---|
| Price | $13.73 | $6.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 147.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 7.37% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.25 | $2.38 |
| 52 Week High | $14.78 | $7.11 |
| Indicator | RMT | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 53.14 |
| Support Level | $13.68 | $4.04 |
| Resistance Level | $14.35 | $7.11 |
| Average True Range (ATR) | 0.26 | 0.39 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 17.79 | 46.86 |
Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector, including diversified consumer services, hotels, household durables, leisure products, and luxury goods. Consumer staples sector, including beverages, food, and staples retailing, food products, and personal products, Energy sector, including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors, including healthcare, financials, industrials, IT, telecommunications, and materials.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.